Susan Sloan

1.6k total citations · 1 hit paper
18 papers, 1.2k citations indexed

About

Susan Sloan is a scholar working on Epidemiology, Immunology and Infectious Diseases. According to data from OpenAlex, Susan Sloan has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 5 papers in Immunology and 4 papers in Infectious Diseases. Recurrent topics in Susan Sloan's work include Influenza Virus Research Studies (6 papers), Respiratory viral infections research (5 papers) and Renal Diseases and Glomerulopathies (4 papers). Susan Sloan is often cited by papers focused on Influenza Virus Research Studies (6 papers), Respiratory viral infections research (5 papers) and Renal Diseases and Glomerulopathies (4 papers). Susan Sloan collaborates with scholars based in United States, United Kingdom and Japan. Susan Sloan's co-authors include Donna M. Ambrosino, William D. Thomas, Catherine A. Hay, Brett Leav, Barbra M. Blair, Roger Baxter, Mark D. Leney, Geoffrey Nichol, Israel Lowy and Dale N. Gerding and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Gastroenterology.

In The Last Decade

Susan Sloan

18 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

2010 557 citations Israel Lowy, Deborah C. Molrine et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Susan Sloan

Since Specialization

Citations

This map shows the geographic impact of Susan Sloan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Sloan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Sloan more than expected).

Fields of papers citing papers by Susan Sloan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Sloan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Sloan. The network helps show where Susan Sloan may publish in the future.

Co-authorship network of co-authors of Susan Sloan

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Sloan. A scholar is included among the top collaborators of Susan Sloan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Sloan. Susan Sloan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants 2023 ·Clinical Pharmacology in Drug Development ·Xiaoyan Zhang, Yanlin Wang, Jill Yarbrough, Mohit Mathur, (unknown), Brian J.G. Pereira, Susan Sloan, Asher D. Schachter	2
2	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers 2022 ·Kidney International Reports ·Mohit Mathur, Jonathan Barratt, Yusuke Suzuki, (unknown), Marcela F. Pasetti, Jill Yarbrough, Susan Sloan, David Oldach	28
3	MO258SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY 2021 ·Nephrology Dialysis Transplantation ·Yusuke Suzuki, Mohit Mathur, Jonathan Barratt, (unknown), Jill Yarbrough, Susan Sloan, David Oldach	6
4	Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study 2020 ·Antiviral Research ·Susan Sloan, Kristy J. Szretter, Bharathi Sundaresh, Kristin Narayan, Patrick F. Smith, David Skurnik, Sylvain Bédard, José Trevejo, David Oldach, Zachary Shriver	20
5	A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy 2019 ·Kidney International ·James R. Myette, Toshiki Kano, Hitoshi Suzuki, Susan Sloan, Kristy J. Szretter, Boopathy Ramakrishnan, Hedy Adari, (unknown), (unknown), Zachary Shriver, Andrew M. Wollacott, Yusuke Suzuki, Brian J.G. Pereira	62
6	Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study 2019 ·EBioMedicine ·Ellie Hershberger, Susan Sloan, Kristin Narayan, Catherine A. Hay, Patrick F. Smith, (unknown), Rienk E. Jeeninga, Saskia L. Smits, José Trevejo, (unknown), David Oldach	63
7	Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks 2016 ·EBioMedicine ·Andrew M. Wollacott, Maciej F. Boni, Kristy J. Szretter, Susan Sloan, Mona Yousofshahi, Karthik Viswanathan, Sylvain Bédard, Catherine A. Hay, Patrick F. Smith, Zachary Shriver, José Trevejo	46
8	The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome 2016 ·Antimicrobial Agents and Chemotherapy ·Tatiana Baranovich, Jeremy C. Jones, Marion Russier, Peter Vogel, Kristy J. Szretter, Susan Sloan, Patrick Seiler, José Trevejo, Richard J. Webby, Elena A. Govorkova	43
9	A broadly neutralizing human monoclonal antibody is effective against H7N9 2015 ·Proceedings of the National Academy of Sciences ·Kannan Tharakaraman, Vidya Subramanian, Karthik Viswanathan, Susan Sloan, Hui‐Ling Yen, Dale L. Barnard, Connie Y. H. Leung, Kristy J. Szretter, (unknown), James C. Delaney, Gregory J. Babcock, Gerald N. Wogan, Ram Sasisekharan, Zachary Shriver	65
10	Identification of a Human Monoclonal Antibody To Replace Equine Diphtheria Antitoxin for Treatment of Diphtheria Intoxication 2013 ·Infection and Immunity ·Leila M. Sevigny, (unknown), Kirk J. Rowley, Brett Leav, Peter Cheslock, (unknown), Susan Sloan, William D. Thomas, Gregory J. Babcock, Yang Wang	21
11	Regulation of hindbrainPyyexpression by acute food deprivation, prolonged caloric restriction, and weight loss surgery in mice 2012 ·American Journal of Physiology-Endocrinology and Metabolism ·Çiğdem Gelegen, (unknown), Agharul I. Choudhury, (unknown), Ian Evans, Elaine E. Irvine, (unknown), Marc Claret, Fabrizio Andréelli, Susan Sloan, Andrew B. Leiter, Dominic J. Withers, Rachel L. Batterham	12
12	G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates 2011 ·Antiviral Research ·Yang Wang, Kirk J. Rowley, (unknown), Susan Sloan, Donna M. Ambrosino, Gregory J. Babcock	25
13	Treatment with Monoclonal Antibodies against Clostridium difficile Toxins breakdown → 2010 ·New England Journal of Medicine ·Israel Lowy, Deborah C. Molrine, Brett Leav, Barbra M. Blair, Roger Baxter, Dale N. Gerding, Geoffrey Nichol, William D. Thomas, Mark D. Leney, Susan Sloan, Catherine A. Hay, Donna M. Ambrosino	557
14	281 SAFETY AND PHARMACOKINETICS OF A NOVEL HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE E2 GLYCOPROTEIN OF HEPATITIS C VIRUS (MBL-HCV1) IN HEALTHY VOLUNTEERS 2010 ·Journal of Hepatology ·Brett Leav, Susan Sloan, (unknown), Peter Cheslock, (unknown), D M Ambrosino, Deborah C. Molrine	2
15	Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus 2009 ·Journal of Virology ·Teresa J. Broering, (unknown), Naomi K. Boatright, Susan Sloan, Frantisek Sandor, William D. Thomas, Gyöngyi Szabó, Robert W. Finberg, Donna M. Ambrosino, Gregory J. Babcock	148
16	751b Phase II Efficacy of Human Monoclonal Antibody Treatment to Prevent C. difficile Recurrence 2009 ·Gastroenterology ·Israel Lowy, Brett Leav, Barbra M. Blair, Roger Baxter, Dale N. Gerding, Geoffrey Nichol, Robert Kohberger, Mark D. Leney, Susan Sloan, Deborah C. Molrine, Donna M. Ambrosino	1
17	Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates 2006 ·Vaccine ·Susan Sloan, Cathleen A. Hanlon, William C. Weldon, Michael Niezgoda, Jesse D. Blanton, (unknown), Kirk J. Rowley, Robert B. Mandell, Gregory J. Babcock, William D. Thomas, Charles E. Rupprecht, Donna M. Ambrosino	70
18	Resistance to Murine Hepatitis Virus Strain 3 Is Dependent on Production of Nitric Oxide 1998 ·Journal of Virology ·Melissa Pope, Philip A. Marsden, Edward Cole, Susan Sloan, L. S. Fung, Qing Ning, Jie Ding, Julian L. Leibowitz, M. James Phillips, Gary Levy	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact